Chronic hepatitis C (CHC) is associated with a higher risk of developing type 2 diabetes mellitus (DM). In patients with preexisting type 2 DM, CHC often worsens glycemic control. With direct-acting antivirals (DAAs)-based treatment regimens for CHC, nearly all patients achieve sustained virologic response (SVR). There is limited literature demonstrating improvement in the glycemic index of patients with DM following the eradication of hepatitis C virus (HCV) with DAA. Thus, it is reasonable to hypothesize that early treatment of CHC and optimal glycemic control in these patients could prevent chronic complications of diabetes and worsening of liver disease. We performed a retrospective cohort study examining whether HCV eradication with DAAs leads to improved glycemic index in patients with DM and the feasibility of safely and successfully offering such care at a primary care physician/providers (PCP) office
